News

2021: A Year in Review at Indica Labs

As 2021 draws to a close, the team at Indica Labs would like to take this opportunity to reflect on the year and to thank our customers for their continued support through this second pandemic year. Despite the ongoing challenges that the pandemic presents, we celebrate the achievements of our customers who have published over 250 publications in peer-reviewed journals this year with an impressive average impact factor of 9.12. To learn more about these publications spanning immuno-oncology, oncology, immunology, infectious disease, and neurology, read our high-impact publications guide and visit our Literature page.

2021: A Year in Review at Indica Labs Read More »

Tumor-specific tumor-resident cytotoxic T cells predict recurrence in stage III melanoma patients treated with adjuvant immunotherapy

20 January 2022 | In this 60-minute webinar, learn how HALO and HALO AI collaborate to perform tissue and cell segmentation, quantification of T-cell subsets in tumor regions, and spatial analysis .

Tumor-specific tumor-resident cytotoxic T cells predict recurrence in stage III melanoma patients treated with adjuvant immunotherapy Read More »

A Deep Learning Convolutional Neural Network Can Differentiate Between Helicobacter Pylori Gastritis and Autoimmune Gastritis with Results Comparable to Gastrointestinal Pathologists

13 January 2022 | In this 60-minute webinar, researchers and pathologists from the University of New Mexico will discuss their recently published study using the HALO AI deep learning convolutional neural network (CNN) to determine whether a CNN can differentiate autoimmune gastritis from Helicobacter pylori gastritis.

A Deep Learning Convolutional Neural Network Can Differentiate Between Helicobacter Pylori Gastritis and Autoimmune Gastritis with Results Comparable to Gastrointestinal Pathologists Read More »

Bench-to-Bedside Transition of Novel HALO® Assays into Clinical Trials with HALO AP®

10 December 2021 | In this 1-hour webinar, featured speakers will demonstrate end-to-end how to develop a quantitative assay in HALO and transition it into clinical trials using HALO AP.

Bench-to-Bedside Transition of Novel HALO® Assays into Clinical Trials with HALO AP® Read More »

Leveraging the collaborative image management platform, HALO Link, for multi-site image analysis collaborations

03 December 2021 | In this webinar you will learn how the Pharma Services team at Indica Labs uses HALO Link to collaborate with customers, to launch and display image analysis results, and to archive studies

Leveraging the collaborative image management platform, HALO Link, for multi-site image analysis collaborations Read More »

2021 Masterclass: Deep Dive into AI-Based Nuclear Segmentation and Phenotyping Part II

04 November 2021 | Following up on our HALO 3.2 Masterclass: Deep Dive into AI-based Nuclear Segmentation and Phenotyping, in this Masterclass webinar with HALO 3.3, we will further delve into options for AI-based nuclear segmentation and phenotyping.

2021 Masterclass: Deep Dive into AI-Based Nuclear Segmentation and Phenotyping Part II Read More »

Indica Labs HALO® User Group Meeting: Bench-to-Bedside Workflows for Digital Pathology, Image Analysis and AI

30 November 2021 | Indica Labs is pleased to announce our 7th Annual HALO® User Group Meeting to be held in conjunction with the Digital Pathology & AI Congress in London on 30 Tuesday November from 12:00 to 16:00. A lunch will be provided to all pre-registered attendees.

Indica Labs HALO® User Group Meeting: Bench-to-Bedside Workflows for Digital Pathology, Image Analysis and AI Read More »

Automated detection and quantitation of gastric immune cells in a mouse model of Helicobacter pylori­-driven preneoplastic progression

21 October 2021 | Gastric cancer is the fourth-leading cause of cancer death worldwide. About 80% of cases are attributable to infection with the bacterium Helicobacter pylori (Hp). Untreated Hp infection causes lifelong stomach inflammation that does not eradicate the bacterium. In some individuals, stomach inflammation leads to preneoplastic progression, a series of sequential tissue changes including loss of gastric acid-producing parietal cells, metaplasia, dysplasia, and finally cancer.

Automated detection and quantitation of gastric immune cells in a mouse model of Helicobacter pylori­-driven preneoplastic progression Read More »

CD38 in the Prostate Tumor Microenvironment

6 October 2021 | CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumor immune evasion. Its expression and role in prostate tumor-infiltrating immune cells (TIICs) have not been elucidated.

CD38 in the Prostate Tumor Microenvironment Read More »

Scroll to Top